Prognostic role of EGR1 in breast cancer: a systematic review.
Biomarkers, Tumor
/ metabolism
Breast Neoplasms
/ metabolism
DNA Methylation
/ genetics
Databases, Genetic
Early Growth Response Protein 1
/ genetics
Female
Gene Expression
/ genetics
Gene Expression Regulation, Neoplastic
/ genetics
Genes, Tumor Suppressor
Humans
Kaplan-Meier Estimate
Prognosis
Promoter Regions, Genetic
/ genetics
Transcriptome
/ genetics
Journal
BMB reports
ISSN: 1976-670X
Titre abrégé: BMB Rep
Pays: Korea (South)
ID NLM: 101465334
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
07
07
2021
pubmed:
8
9
2021
medline:
4
2
2022
entrez:
7
9
2021
Statut:
ppublish
Résumé
EGR1 (early growth response 1) is dysregulated in many cancers and exhibits both tumor suppressor and promoter activities, making it an appealing target for cancer therapy. Here, we used a systematic multi-omics analysis to review the expression of EGR1 and its role in regulating clinical outcomes in breast cancer (BC). EGR1 expression, its promoter methylation, and protein expression pattern were assessed using various publicly available tools. COSMIC-based somatic mutations and cBioPortal-based copy number alterations were analyzed, and the prognostic roles of EGR1 in BC were determined using Prognoscan and Kaplan-Meier Plotter. We also used bc-GenEx- Miner to investigate the EGR1 co-expression profile. EGR1 was more often downregulated in BC tissues than in normal breast tissue, and its knockdown was positively correlated with poor survival. Low EGR1 expression levels were also associated with increased risk of ER+, PR+, and HER2- BCs. High positive correlations were observed among EGR1, DUSP1, FOS, FOSB, CYR61, and JUN mRNA expression in BC tissue. This systematic review suggested that EGR1 expression may serve as a prognostic marker for BC patients and that clinicopathological parameters influence its prognostic utility. In addition to EGR1, DUSP1, FOS, FOSB, CYR61, and JUN can jointly be considered prognostic indicators for BC. [BMB Reports 2021; 54(10): 497-504].
Substances chimiques
Biomarkers, Tumor
0
EGR1 protein, human
0
Early Growth Response Protein 1
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
497-504Références
Genes Genomics. 2021 May;43(5):459-470
pubmed: 33687657
Int J Mol Sci. 2015 Jan 22;16(2):2472-96
pubmed: 25622259
Oncol Lett. 2018 Aug;16(2):1869-1875
pubmed: 30008878
Int J Clin Exp Pathol. 2017 Oct 01;10(10):10212-10222
pubmed: 31966355
BMC Cancer. 2009 Oct 30;9:385
pubmed: 19878561
Anal Chim Acta. 2019 Jan 10;1046:154-162
pubmed: 30482293
Cancer Genomics Proteomics. 2007 Nov-Dec;4(6):377-85
pubmed: 18204200
Hepatoma Res. 2017;3:268-277
pubmed: 29607419
Oncotarget. 2017 Feb 7;8(6):9200-9215
pubmed: 27911269
Biomed Pharmacother. 2013 Apr;67(3):197-202
pubmed: 23478574
Carcinogenesis. 2021 Feb 11;42(1):93-104
pubmed: 32531042
Cancer Med. 2016 Aug;5(8):2061-8
pubmed: 27227569
Oncogene. 2005 Sep 29;24(43):6516-24
pubmed: 16027729
J Exp Clin Cancer Res. 2017 Dec 15;36(1):186
pubmed: 29246166
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Anticancer Res. 2009 Apr;29(4):1111-7
pubmed: 19414352
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
J Clin Oncol. 2005 Mar 20;23(9):1921-6
pubmed: 15774784
Rev Endocr Metab Disord. 2004 Aug;5(3):249-54
pubmed: 15211096
J Biol Chem. 2010 Jan 15;285(3):1643-52
pubmed: 19915002
BMC Med Genomics. 2009 Apr 24;2:18
pubmed: 19393097
J Cell Physiol. 2002 Dec;193(3):287-92
pubmed: 12384981
Front Behav Neurosci. 2017 Mar 06;11:35
pubmed: 28321184
J Mammary Gland Biol Neoplasia. 2003 Jan;8(1):45-73
pubmed: 14587863
Pathol Res Pract. 2013 Nov;209(11):692-9
pubmed: 24011795
Oncotarget. 2018 Apr 6;9(26):18084-18098
pubmed: 29719592
Sci Rep. 2021 Jan 12;11(1):491
pubmed: 33436746
Neoplasia. 2007 Feb;9(2):166-80
pubmed: 17356713
Mol Cells. 2019 Dec 31;42(12):884-892
pubmed: 31735020
Int J Mol Sci. 2020 Feb 28;21(5):
pubmed: 32121305
Cancer Gene Ther. 2006 Feb;13(2):115-24
pubmed: 16138117
Epigenetics Chromatin. 2015 Jun 23;8:22
pubmed: 26113876
Bio Protoc. 2019 Dec 20;9(24):
pubmed: 31867411
Genes Chromosomes Cancer. 2012 Mar;51(3):300-12
pubmed: 22095904
World J Clin Oncol. 2014 Aug 10;5(3):283-98
pubmed: 25114845
Sci Rep. 2018 Jun 15;8(1):9227
pubmed: 29907753
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
J Biol Chem. 2009 Dec 11;284(50):34600-6
pubmed: 19837667
Cancer Cell. 2002 Dec;2(6):485-95
pubmed: 12498717
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Cancers (Basel). 2016 Feb 25;8(3):
pubmed: 26927176
Cancer Biol Ther. 2003 Nov-Dec;2(6):617-22
pubmed: 14688464
Database (Oxford). 2013 Jan 15;2013:bas060
pubmed: 23325629
Sci Rep. 2018 Oct 4;8(1):14806
pubmed: 30287838
Sci Rep. 2016 Sep 19;6:33524
pubmed: 27642033
Cell Prolif. 2021 Jan;54(1):e12922
pubmed: 33145887
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Exp Mol Med. 2012 May 31;44(5):356-62
pubmed: 22333693
J Clin Med. 2019 Mar 13;8(3):
pubmed: 30871151
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
Oncotarget. 2017 May 30;8(57):96865-96884
pubmed: 29228577
J Clin Med. 2019 Apr 15;8(4):
pubmed: 30991713
Science. 1987 Nov 6;238(4828):797-9
pubmed: 3672127
Science. 2015 Sep 25;349(6255):1483-9
pubmed: 26404825
Front Oncol. 2019 Oct 23;9:1074
pubmed: 31709177
Carcinogenesis. 2000 Dec;21(12):2175-81
pubmed: 11133806
Eur J Gynaecol Oncol. 2006;27(4):345-52
pubmed: 17009623
Oncol Lett. 2018 Aug;16(2):2757-2763
pubmed: 30013671
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
J Med Life. 2015;8(Spec Iss 4):6-11
pubmed: 28316699
Front Genet. 2021 Jun 09;12:680132
pubmed: 34178038
Future Oncol. 2009 Sep;5(7):993-1003
pubmed: 19792968
Sci Rep. 2014 Jul 03;4:5416
pubmed: 24990820
Neoplasia. 2004 Jan-Feb;6(1):1-6
pubmed: 15068665
PLoS One. 2016 Feb 09;11(2):e0148065
pubmed: 26859151
Cell Stem Cell. 2008 Apr 10;2(4):380-91
pubmed: 18397757
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Oncol Rep. 2014 Feb;31(2):788-94
pubmed: 24297681